20/20 HealthCare Partners LLC — Full Portfolio
17 tracked investments · listed companies and verified rows first
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investorsBosch VenturesNew Era Capital PartnersOrbiMedPeregrine VenturesPitangoQuark Venture Inc.+2 more
Portable, connected precision-medicine platform for coagulation management.
PartnerHillel Bachrach· solo GP
HealthtechWaltham, US
Stephen J. Lemaster(Executive Officer)Mark J. Toland(Executive Officer, Director)David W. Long(Executive Officer)Jeffrey C Lightcap(Chairman)David W Long(Executive Officer)Michael Mashaal(Director)
PartnerHillel Bachrach· led
Co-investorsBioStar Ventures
Developing device-based therapies to treat neurodegenerative diseases such as ALS and PSP.
PartnerHillel Bachrach· solo GP
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Anthony DePasqua(Executive Officer, Director)inJason Camm(Director)Kasper Roet(Director)Tony DePasqua(President & CEO)Kevin Kalish(COO)Marcie Glicksman(VP Biology)
PartnerHillel Bachrach· led
Co-investorsFlucas VenturesTachyon VenturesVU Venture PartnersDolby Family Ventures
AI imaging platform for oncology care that tracks patient journeys and analyzes disease progression.
PartnerHillel Bachrach· solo GP
Medical diagnostic platform analyzing protein function for neurodegenerative disease and oncology, including a blood-based ALS diagnostic.
PartnerHillel Bachrach· solo GP
HealthtechNaperville, US
Matthew Pipke(Executive Officer, Director, Promoter)Gary Conkright(Executive Officer, Director, Promoter)
BoardRobert Lynch(Director)Edward Michael(Director)David Ormesher(Director)
PartnerHillel Bachrach· solo GP
UK IP development company creating medical diagnostic technologies analyzing protein/nucleic acid interactions.
PartnerHillel Bachrach· solo GP
Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer.
BiotechHealthtechRockville, US
Gregory Plan Crimmins(Executive Officer, Director)
PartnerHillel Bachrach· solo GP
Co-investorsSchooner Capital
Biotech delivery company named a Fierce 15 biotech company.
PartnerHillel Bachrach· solo GP
Provider of dose and procedure-time reduction software for nuclear medicine; sold to Pharmalogic in 2019.
PartnerHillel Bachrach· solo GP
Verseau develops cancer immunotherapies based on macrophage repolarization, converting immuno-suppressive M2 macrophages into pro-inflammatory M1 macrophages to trigger an immune response against tumors.
BiotechHealthtechAuburndale, US
Walter Capone(Executive Officer)Christine Bunt(Executive Officer, Director)Daniel Anderson(Executive Officer, Director, Promoter)
BoardRobert Langer(Director, Promoter)Jong Chang(Director)
PartnerHillel Bachrach· led
Provider of digital radiography hardware and software solutions; acquired by Konica Minolta in 2015.
PartnerHillel Bachrach· solo GP
XR therapeutics platform company that merged with Amelia Virtual Care.
PartnerHillel Bachrach· solo GP
Co-investorsAsabys PartnersBridges IsraelFlying Tiger Capital
Zixi provides software for reliable video delivery over unpredictable IP networks, using patented hitless failover, multi-path bonding, and adaptive error correction to recover from packet loss.
Cloud ComputingMedia & EntertainmentSaaS
PartnerHillel Bachrach· led
Co-investorsSchooner Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.